⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11123493 | 0.87 | — | — | |
| SCHEMBL11125378 | 0.83 | — | — | |
| SCHEMBL4401199 | 0.81 | ADRA2A (0.45) | — | |
| SCHEMBL1726232 | 0.78 | SMN1; SMN2 (0.43) | — | |
| SCHEMBL24533674 | 0.77 | — | — | |
| SCHEMBL32681385 | 0.77 | ADRA2A (0.43) | — | |
| SCHEMBL23613101 | 0.77 | ADRA2A (0.39) | — | |
| SCHEMBL8707780 | 0.77 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL11123146 | 0.77 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL11123645 | 0.77 | SMN1; SMN2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270912-A1 | Water-Soluble Films and Methods of Use | CMC Group, Inc. | 2024-08-15 | — | — | US | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240207306-A1 | COMPOSITION CONTROLLING PHARMACOKINETICS IN THE BODY | KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240207306-A1 | COMPOSITION CONTROLLING PHARMACOKINETICS IN THE BODY | KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-4388070-A1 | WATER-SOLUBLE FILMS AND METHODS OF USE | Nohbo, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-118206745-A | Compounds and blocking agents comprising the same | 菲鹏生物股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-118139961-A | Water-soluble films and methods of use | 诺赫博股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20230398140-A1 | OCULAR-TENSION-INCREASING AGENT CAPABLE OF BEING DEPRIVED OF DRUG ACTIVITY BY TEMPERATURE CONTROL | UNIVERSITY OF YAMANASHI (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230398140-A1 | OCULAR-TENSION-INCREASING AGENT CAPABLE OF BEING DEPRIVED OF DRUG ACTIVITY BY TEMPERATURE CONTROL | UNIVERSITY OF YAMANASHI (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230295139-A1 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS FROM CARBOXAMIDE AND CARBOXAMIDE DERIVATIVES WITH HALOALKANOLS | UNIVERSITY OF KWAZULU-NATAL (ZA) | 2023-09-21 | — | — | US | disclosed |
| US-7312235-B2 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312235-B2 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7285565-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7285565-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7262186-B2 | Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| EP-0030350-B1 | METHOD FOR REDUCING THE TERMINAL CARBOXYL GROUP CONTENT OF A SATURATED POLYESTER, A SATURATED POLYESTER HAVING A REDUCED TERMINAL CARBOXYL GROUP CONTENT, AND A MOLDED ARTICLE COMPOSED OF SUCH A SATURATED POLYESTER | TEIJIN LIMITED (JP) | 1984-10-10 | — | — | EP | disclosed |
| US-4351936-A | COMPRISING ENDCAPPING WITH AN OXAZOLINE OR OXAZINE | TEIJIN LIMITED (JP) | 1982-09-28 | — | — | US | disclosed |
| EP-0030350-A1 | Method for reducing the terminal carboxyl group content of a saturated polyester, a saturated polyester having a reduced terminal carboxyl group content, and a molded article composed of such a saturated polyester | TEIJIN LIMITED (JP) | 1981-06-17 | — | — | EP | disclosed |